Masaki Shimoji

1.6k total citations · 1 hit paper
38 papers, 1.1k citations indexed

About

Masaki Shimoji is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Masaki Shimoji has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Masaki Shimoji's work include Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (6 papers). Masaki Shimoji is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Research Studies (6 papers). Masaki Shimoji collaborates with scholars based in Japan, United States and Austria. Masaki Shimoji's co-authors include Tetsuya Mitsudomi, Kenichi Suda, Toshiki Takemoto, Kenji Tomizawa, Yoshihisa Kobayashi, Masato Chiba, Toshio Fujino, Shuta Ohara, T. Koga and Masaya Nishino and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Cancer Research and European Journal of Cancer.

In The Last Decade

Masaki Shimoji

35 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

2021 167 citations T. Koga, Kenichi Suda et al. Journal of Thoracic Oncology profile →

Peers

Masaki Shimoji

PRM

ONCOL

PFM

Toshiki Takemoto Japan

Gonzalo Recondo United States

Dana Ghiorghiu United Kingdom

Hirokazu Ogino Japan

Aleksandra Markovets United States

Erina Hatashita Japan

Vladimir Vladimirov United States

Kiyoko Kuwata Japan

Erzsébet Juhász Hungary

Toshiki Takemoto Japan

Masaki Shimoji

616 ×0.8

PRM

527 ×0.8

ONCOL

381 ×0.9

161 ×0.8

83 ×0.9

PFM

Citations per year, relative to Masaki Shimoji Masaki Shimoji (= 1×) peers Toshiki Takemoto

Countries citing papers authored by Masaki Shimoji

Since Specialization

Citations

This map shows the geographic impact of Masaki Shimoji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masaki Shimoji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masaki Shimoji more than expected).

Fields of papers citing papers by Masaki Shimoji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masaki Shimoji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masaki Shimoji. The network helps show where Masaki Shimoji may publish in the future.

Co-authorship network of co-authors of Masaki Shimoji

This figure shows the co-authorship network connecting the top 25 collaborators of Masaki Shimoji. A scholar is included among the top collaborators of Masaki Shimoji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masaki Shimoji. Masaki Shimoji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ohara, Shuta, Kenichi Suda, Akira Hamada, et al.. (2024). Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer. Thoracic Cancer. 15(31). 2229–2234. 1 indexed citations

Hamada, Akira, Kenichi Suda, Masaya Nishino, et al.. (2023). Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion. Journal of Thoracic Oncology. 19(1). 71–79. 9 indexed citations

Koga, T., Junichi Soh, Akira Hamada, et al.. (2023). Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing. JTO Clinical and Research Reports. 4(9). 100554–100554. 4 indexed citations

Hamada, Akira, Kenichi Suda, Toshio Fujino, et al.. (2022). Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC. JTO Clinical and Research Reports. 3(5). 100321–100321. 7 indexed citations

Ohara, Shuta, Kenichi Suda, Toshio Fujino, et al.. (2021). Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. Lung Cancer. 154. 84–91. 10 indexed citations

Takemoto, Toshiki, Junichi Soh, Shuta Ohara, et al.. (2021). The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery. Surgery Today. 51(9). 1480–1487. 7 indexed citations

Ohara, Shuta, Kenichi Suda, Kenji Tomizawa, et al.. (2020). Prognostic value of plasma fibrinogen and d-dimer levels in patients with surgically resected non-small cell lung cancer. Surgery Today. 50(11). 1427–1433. 15 indexed citations

Ohara, Shuta, Kenji Tomizawa, Shigeki Shimizu, et al.. (2019). Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. SHILAP Revista de lepidopterología. 5(1). 105–105.

Fujino, Toshio, Yoshihisa Kobayashi, Kenichi Suda, et al.. (2019). Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. Journal of Thoracic Oncology. 14(10). 1753–1765. 114 indexed citations

10.

Fujino, Toshio, Kenichi Suda, Yoshihisa Kobayashi, et al.. (2018). P1.13-41 In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping. Journal of Thoracic Oncology. 13(10). S598–S598. 1 indexed citations

11.

Suda, Kenichi, Jihye Kim, Isao Murakami, et al.. (2018). Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. Journal of Thoracic Oncology. 13(10). 1496–1507. 21 indexed citations

12.

Kinoshita, Tomonari, Chie Kudo‐Saito, Reiko Muramatsu, et al.. (2017). Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. European Journal of Cancer. 86. 15–27. 60 indexed citations

13.

Tomizawa, Kenji, Shigeki Shimizu, Shuta Ohara, et al.. (2017). Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. Lung Cancer. 112. 57–61. 11 indexed citations

14.

Kobayashi, Yoshihisa, Koichi Azuma, Hiroki Nagai, et al.. (2016). Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Molecular Cancer Therapeutics. 16(2). 357–364. 57 indexed citations

15.

Suda, Kenichi, Isao Murakami, Hui Yu, et al.. (2016). Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. Journal of Thoracic Oncology. 11(10). 1711–1717. 12 indexed citations

16.

Tomizawa, Kenji, Masaya Nishino, Yoshihisa Kobayashi, et al.. (2016). Prognostic impact of pleural lavage cytology in patients with primary lung cancer. Lung Cancer. 102. 60–64. 9 indexed citations

17.

Kobayashi, Yoshihisa, Yosuke Togashi, Yasushi Yatabe, et al.. (2015). EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clinical Cancer Research. 21(23). 5305–5313. 164 indexed citations

18.

Abe, Masato, Masaki Shimoji, Tomohiro Maniwa, et al.. (2014). Pulmonary adenosquamous carcinoma with mucoepidermoid carcinoma-like component with characteristic p63 staining pattern: Either a novel subtype originating from bronchial epithelium or variant mucoepidermoid carcinoma. Lung Cancer. 84(1). 45–50. 7 indexed citations

19.

Takeuchi, Kengo, Masaki Shimoji, Tomohiro Maniwa, et al.. (2012). Small non‐mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: A novel ALK fusion gene?. Cancer Science. 103(2). 390–392. 5 indexed citations

20.

Shimoji, Masaki, Takashi Nakajima, Mitsuhiro Isaka, et al.. (2011). A clinicopathological and immunohistological re‐evaluation of adenosquamous carcinoma of the lung. Pathology International. 61(12). 717–722. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact